Evidence map›Paper›PMID 42232305›Full record

ArticleFrontiers in cardiovascular medicine2026

Complete revascularization and heart failure risk in acute coronary syndrome across the ejection fraction spectrum: focus on LVEF-dependent effects.

Xiaozhi Luo, Jiaan Nong, Shaowei Xu, Zhongyuan Meng, Xingshou Pan

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaozhi LuoDepartment of Cardiology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.
Jiaan NongDepartment of Psychosomatic Medicine, Guangxi Zhuang Autonomous Region Brain Hospital, Liuzhou, Guangxi, China.
Shaowei XuDepartment of Cardiology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.
Zhongyuan MengDepartment of Cardiology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.
Xingshou PanDepartment of Cardiology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the impact of complete revascularization (CR) versus incomplete revascularization (ICR) on the composite outcome of first hospitalization for heart failure (HF) or cardiovascular death in patients with acute coronary syndrome (ACS) and a left ventricular ejection fraction (LVEF) ≥ 40%. Methods: This retrospective study enrolled 1,834 patients with ACS, multivessel disease, and an LVEF ≥ 40% (767 CR and 1,067 ICR). CR was defined as percutaneous coronary intervention (PCI) of all suitable non-culprit lesions during index hospitalization or within 45 days postdischarge. The primary endpoint was the first occurrence of hospitalization for HF or cardiovascular death. At discharge, almost all patients received dual antiplatelet therapy and guideline-directed medical therapy. Result: During the follow-up period, 35 of the 767 patients (4.6%) in the CR group and 83 of the 1,067 (7.8%) patients in the ICR group reached the primary endpoint ( Conclusion: CR is associated with a significantly reduced risk of HF hospitalization or cardiovascular death in patients with an LVEF of 40%-50%. This benefit attenuated as the LVEF increased, highlighting a potential LVEF-dependent efficacy. Although these results are promising, the observational nature of this study and the potential for residual confounding necessitate cautious interpretation.

Indexed as

acute coronary syndromecomplete revascularizationheart failureleft ventricular ejection fractionmultivessel disease

Identifiers

PMID42232305
PMCPMC13223025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.